Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 6/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28245363 | 0.93 | IMPDH2 (0.45) | IMPDH2PRMT3ROCK2ROCK1CYP3A4 | |
| SCHEMBL29069418 | 0.83 | IMPDH2 (0.50) | IMPDH2PRMT3ROCK2ROCK1CYP3A4 | |
| SCHEMBL27689981 | 0.82 | ALDH1A1 (0.50) | CYP3A4 | |
| SCHEMBL12298503 | 0.78 | EPHX2 (0.44) | CYP3A4 | |
| SCHEMBL28152569 | 0.76 | NPC1 (0.41) | IMPDH2 | |
| SCHEMBL28170955 | 0.76 | NPC1 (0.41) | IMPDH2 | |
| SCHEMBL29069445 | 0.76 | IMPDH2 (0.43) | IMPDH2PRMT3ROCK2ROCK1CYP3A4 | |
| SCHEMBL24783504 | 0.76 | IMPDH2 (0.53) | IMPDH2PRMT3ROCK2ROCK1CYP3A4 | |
| SCHEMBL11143193 | 0.76 | MAPT (0.56) | IMPDH2PRMT3ROCK2ROCK1CYP3A4 | |
| SCHEMBL14641399 | 0.75 | IMPDH2 (0.53) | IMPDH2PRMT3ROCK2ROCK1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105163727-B | Stimulate neurogenetic isoquinilone derivatives | 豪夫迈·罗氏有限公司 | 2018-08-17 | — | — | CN | claimed |
| CN-106458912-A | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2017-02-22 | — | — | CN | claimed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | claimed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | claimed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| CN-105814040-B | The condensed 1,4- dihydro two of inhibitor as thermal excited transcryption factor 1 dislikes ene derivative | 癌症研究科技有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109310690-A | Isoquinolin -3- base benzamide type and its preparation and its purposes | 萨穆梅德有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109134367-A | A kind of compound and application thereof inhibiting ROCK | 成都先导药物开发有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109153643-A | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2019-01-04 | — | — | CN | disclosed |
| CN-105143200-B | Serine/threonine kinase inhibitor for treating excess proliferative disease | 阵列生物制药公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-105163727-B | Stimulate neurogenetic isoquinilone derivatives | 豪夫迈·罗氏有限公司 | 2018-08-17 | — | — | CN | disclosed |
| CN-108203433-A | A kind of ROCK inhibitor and its application | 成都先导药物开发有限公司 | 2018-06-26 | — | — | CN | disclosed |
| CN-107428692-A | Substituted monoazanaphthalene derivatives and polyazanaphthalene derivatives and use thereof | 巴斯利尔药物国际股份公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-106817900-A | Novel naphthyridines and isoquinolin and its purposes as CDK8/19 inhibitor | 默克专利有限公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-106458912-A | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2017-02-22 | — | — | CN | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | IMPDH2 475/4885PRMT3 2386/4885ROCK2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.